The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta‐review of meta‐analyses of randomized controlled trials

The researchers aggregated all available meta-analyses of randomized controlled trials (RCTs) testing nutrient supplements for mental disorders. The supplements tested included:

**Polyunsaturated fatty acids (PUFAs)** – primarily omega-3 fish oils containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)

**Folate-based supplements** – including folic acid, methylfolate (the active form), and folinic acid

**N-acetylcysteine (NAC)** – an amino acid with antioxidant properties

**Vitamins** – including vitamin D, vitamin B12, vitamin B6, and other B vitamins

**Minerals** – including zinc, magnesium, and chromium

**Amino acids** – including S-adenosyl methionine (SAMe), tryptophan, glycine, and taurine

**Pre/probiotics** – specific strains of gut bacteria or compounds that promote their growth

**Other antioxidants** – including alpha-lipoic acid, coenzyme Q10, and inositol

The comparators were always placebo (inactive pills). The primary outcome was improvement in symptoms of the target mental disorder, measured by validated clinician-rated or self-report scales.

The mental disorders studied included: major depressive disorder, bipolar disorder (types I and II), schizophrenia and other psychotic disorders, attention-deficit/hyperactivity disorder (ADHD), anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and personality disorders.

The meta-review included data from 33 separate meta-analyses, which collectively contained outcome data from **10,951 individuals** across all primary analyses. The individual studies within those meta-analyses included:

Adults (aged 18–65+) with confirmed diagnoses of mental disorders (at least 75% of each sample had a clinical diagnosis or met validated screening thresholds)

Both medicated and unmedicated participants

People from inpatient and outpatient settings across multiple countries (primarily Western nations, but also including some Asian and Middle Eastern studies)

Some studies of children and adolescents (particularly for ADHD)

Studies of people at "ultra-high risk" for psychosis

The specific sample sizes for each supplement-disorder combination varied widely. For example, the depression-PUFA meta-analyses included over 2,000 participants across multiple trials, while the evidence for NAC in schizophrenia came from smaller samples (typically 100–400 participants across trials).

The researchers extracted data from published meta-analyses that had already pooled results from individual RCTs. The outcome measures varied by disorder:

**Depression:** Standardized mean difference (SMD) on clinician-rated scales like the Hamilton Depression Rating Scale (HAM-D, 0–52, higher = more depressed) or the Montgomery-Åsberg Depression Rating Scale (MADRS, 0–60, higher = more depressed), or self-report scales like the Beck Depression Inventory (BDI, 0–63, higher = more depressed)

**Schizophrenia:** Positive and Negative Syndrome Scale (PANSS, 30–210, higher = more severe symptoms) or the Brief Psychiatric Rating Scale (BPRS)

**ADHD:** Conners' Rating Scales or clinician-rated ADHD symptom scales

**Bipolar disorder:** Young Mania Rating Scale (YMRS) for mania, or depression rating scales for bipolar depression

**Anxiety:** Hamilton Anxiety Rating Scale (HAM-A, 0–56, higher = more anxious)

The researchers also extracted data on:

**Response rates** (percentage of participants who achieved ≥50% symptom reduction)

**Remission rates** (percentage who fell below diagnostic threshold)

**Dropout rates** (as a proxy for tolerability)

**Adverse events** (specific side effects reported)

### Study design

This is a **meta-review** (also called an "umbrella review") – a systematic synthesis of existing meta-analyses. The researchers:

1. **Pre-registered** their protocol (PROSPERO: CRD42018105880) before starting

2. **Systematically searched** six databases (Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Health Technology Assessment Database, AMED, PsycINFO, and Ovid MEDLINE) from inception to February 1, 2019

3. **Also searched** Google Scholar and reference lists of included articles

4. **Applied strict eligibility criteria** – only included meta-analyses of placebo-controlled RCTs in people with confirmed mental disorders (≥75% of sample)

5. **Extracted data** on: supplement type, dose, disorder, number of RCTs, total participants, effect sizes, heterogeneity, and quality of evidence

6. **Assessed quality** of each included meta-analysis using AMSTAR (A Measurement Tool to Assess Systematic Reviews)

### Why this design matters

A meta-review sits at the top of the evidence hierarchy. Rather than looking at individual studies (which can be misleading due to small samples or publication bias), it aggregates the highest-level evidence. This is particularly important for nutrient supplements because:

**Many small positive trials exist** that later fail to replicate – a meta-review can detect this pattern

**Different meta-analyses of the same topic can disagree** – this review compares them side-by-side

**Safety data across multiple trials** provides better estimates of rare adverse events

### What this design can and cannot prove

**Can prove:**

Which supplement-disorder combinations have consistent evidence across multiple independent trials

The overall direction and approximate magnitude of effects

Whether effects are robust across different populations and settings

Relative safety profiles across supplements

**Cannot prove:**

Causality in any individual trial (that requires the original RCT design)

Which specific individuals will respond (the "average effect" may not apply to you)

Optimal dosing for individuals (most meta-analyses pool different doses)

Long-term effects beyond typical trial durations (usually 6–16 weeks)

Mechanisms of action (why the supplement works)

### Major methodological strengths

Pre-registered protocol reduces risk of selective reporting

Comprehensive search across multiple databases

Strict inclusion criteria (only placebo-controlled RCTs)

Quality assessment of included meta-analyses

Examined both efficacy and safety

### Major methodological weaknesses

**Publication bias:** Meta-analyses can only include published studies; negative results may be missing

**Heterogeneity:** Different meta-analyses used different inclusion criteria, doses, and outcome measures, making direct comparisons difficult

**Quality variation:** Some included meta-analyses were of low quality (the authors note this)

**Industry funding:** Many individual RCTs were funded by supplement manufacturers (the authors did not systematically assess this)

**No individual patient data:** Cannot examine moderators of response (e.g., age, sex, baseline nutrient levels)

**Outdated search:** The search ended in February 2019, so more recent trials are not included

### Strongest evidence: Omega-3 PUFAs for depression

**Primary outcome:** Omega-3 supplementation (as adjunctive treatment) showed a significant benefit over placebo for depression symptoms

**Effect size:** Standardized mean difference (SMD) = 0.40 (95% CI: 0.28–0.52, p<0.001) – a moderate effect

**Specificity:** Only supplements with **≥60% EPA content** (eicosapentaenoic acid) showed benefit; pure DHA supplements did not

**Dose:** Effective doses ranged from 1–3 g/day of EPA

**Response rate:** Approximately 1.5–2 times more likely to achieve ≥50% symptom reduction compared to placebo

**Number needed to treat (NNT):** Approximately 7–10 (meaning 7–10 people need to be treated for one to benefit beyond placebo)

### Moderate evidence: Methylfolate for depression

**High-dose methylfolate** (15 mg/day) as adjunctive treatment showed benefit in major depressive disorder

**Effect size:** SMD = 0.41 (95% CI: 0.18–0.64) for methylfolate specifically

**Standard folic acid** (0.5–5 mg/day) showed no significant benefit

**Response rate:** Approximately 1.4 times more likely to respond than placebo

### Emerging evidence: N-acetylcysteine (NAC)

**Mood disorders:** NAC showed benefit as adjunctive treatment (SMD = 0.45, 95% CI: 0.17–0.72)

**Schizophrenia:** NAC showed benefit for total symptoms (SMD = 0.34, 95% CI: 0.08–0.60), particularly negative symptoms

**Dose:** Typically 2–3 g/day

**Duration:** Most trials were 8–24 weeks

### Limited or no evidence for:

**Omega-3 for schizophrenia:** No significant benefit (SMD = 0.08, 95% CI: -0.10 to 0.26)

**Omega-3 for ADHD:** Small but significant effect (SMD = 0.17, 95% CI: 0.03–0.31) – clinically questionable

**Vitamin D for depression:** Mixed results; some meta-analyses showed benefit, others did not

**Zinc for depression:** Small effect (SMD = 0.22, 95% CI: 0.01–0.43) but based on few trials

**SAMe for depression:** Positive but based on small, low-quality trials

**Probiotics for depression:** Small effect (SMD = 0.30, 95% CI: 0.10–0.50) but high heterogeneity

**Magnesium for any disorder:** Insufficient evidence

**Chromium for depression:** No significant benefit

**Glycine for schizophrenia:** No significant benefit

**Inositol for OCD or depression:** No significant benefit

### Safety findings

**No serious adverse events** were attributed to any nutrient supplement

**Dropout rates** were similar between supplement and placebo groups across all supplements

**Mild side effects** included: fishy aftertaste (omega-3), gastrointestinal discomfort (NAC, magnesium), and nausea (methylfolate)

**No contraindications** with psychiatric medications were identified

**Omega-3 for depression:** The SMD of 0.40 translates to approximately a **3–5 point greater reduction** on the Hamilton Depression Rating Scale (HAM-D) compared to placebo. To put this in context: a typical antidepressant medication produces an SMD of 0.30–0.50 versus placebo. So omega-3 (EPA-rich) is roughly comparable to standard antidepressants in effect size, but as an *adjunctive* treatment (added to existing medication).

**Methylfolate for depression:** The SMD of 0.41 means that someone taking 15 mg/day of methylfolate alongside their antidepressant would be expected to have about a **4–6 point greater reduction** on the MADRS scale compared to placebo. This is a moderate effect – noticeable but not transformative for most people.

**NAC for schizophrenia:** The SMD of 0.34 for total symptoms means about a **5–8 point greater reduction** on the PANSS scale (30–210 range) compared to placebo. This is a small-to-moderate effect, roughly equivalent to adding a low-dose second antipsychotic.

**Omega-3 for ADHD:** The SMD of 0.17 is very small – equivalent to about a **1–2 point difference** on ADHD rating scales. This is unlikely to be clinically noticeable for most individuals.

### What the authors acknowledge

**Heterogeneity across meta-analyses:** Different inclusion criteria, doses, and outcome measures make direct comparisons difficult

**Publication bias:** Some supplement-disorder combinations had evidence of small-study effects (small positive trials published, larger negative trials unpublished)

**Quality variation:** Some included meta-analyses were rated as low quality on AMSTAR

**Short trial durations:** Most RCTs were 6–16 weeks; long-term effects unknown

**Adjunctive treatment focus:** Most studies tested supplements *added to* existing medication, not as standalone treatments

### What a critical reader would note

**Industry funding:** Many individual RCTs were funded by supplement manufacturers; the authors did not systematically assess or report this

**No correction for multiple comparisons:** Testing many supplement-disorder combinations increases the risk of false positives

**Outdated evidence:** The search ended in February 2019; several important trials have been published since (e.g., larger omega-3 depression trials, newer NAC studies)

**Dose variability:** Within each supplement category, doses varied widely across trials, making it impossible to identify optimal dosing

**Baseline nutrient status not assessed:** Most trials did not measure participants' baseline nutrient levels, so it's unclear if benefits are limited to those with deficiencies

**No individual-level predictors:** Cannot determine who is most likely to respond

**"File drawer" problem:** Negative results from small trials may never be published, inflating effect sizes

**Lack of long-term safety data:** While no serious adverse events were reported in trials lasting 6–16 weeks, long-term safety (years) of high-dose supplements is unknown

For someone running their own n=1 experiment:

### What to test (specific intervention and dose)

**For depression (strongest evidence):**

**EPA-rich omega-3** (≥60% EPA, ≤40% DHA)

**Dose:** 1,000–3,000 mg total EPA per day (e.g., 2,000 mg EPA + 500 mg DHA)

**Form:** Triglyceride form (better absorbed) rather than ethyl ester

**Brand:** Look for third-party tested (e.g., USP, NSF, or ConsumerLab certification)

**For depression (moderate evidence):**

**L-methylfolate** (active form of folate)

**Dose:** 15 mg/day (requires prescription in many countries; over-the-counter versions are typically 1 mg or less)

**Note:** Standard folic acid (0.5–5 mg) is unlikely to work

**For mood disorders or schizophrenia (emerging evidence):**

**N-acetylcysteine (NAC)**

**Dose:** 2,000–3,000 mg/day (typically 1,000–1,500 mg twice daily)

**Form:** Capsules or powder

### Minimum meaningful duration

**Omega-3 for depression:** 8 weeks minimum; effects may take 4–6 weeks to appear

**Methylfolate:** 8–12 weeks minimum

**NAC:** 12–24 weeks minimum (most positive trials were 16–24 weeks)

**General rule:** Run your experiment for at least 8–12 weeks for any supplement

### What to measure (specific metrics)

**Primary outcome (choose one):**

**Depression:** Patient Health Questionnaire-9 (PHQ-9, 0–27, free online) – weekly

**Mood:** Quick Inventory of Depressive Symptomatology (QIDS-SR, 0–27, free online) – weekly

**Schizophrenia symptoms:** If you have access, the PANSS or BPRS (requires clinician)

**ADHD:** Adult ADHD Self-Report Scale (ASRS, 0–72, free online) – weekly

**Secondary outcomes (measure weekly):**

**Sleep quality:** Single item (1–10 scale, 10 = best)

**Energy/fatigue:** Single item (1–10 scale, 10